section name header

Pronunciation

MI-gli-tole

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: alpha glucosidase inhibitors

Indications

REMS


Action

  • Lowers blood glucose by inhibiting the enzyme alpha-glucosidase in the GI tract, resulting in delayed glucose absorption.
Therapeutic effects:
  • Lowering of blood glucose in diabetic patients, especially postprandial hyperglycemia.

Pharmacokinetics

Absorption: Completely absorbed at lower doses (25 mg); 50–70% absorbed at higher doses (100 mg).

Distribution: Distributes primarily into extracellular fluid; small amounts enter breast milk.

Metabolism/Excretion: Not metabolized; action is primarily local in the GI tract; amounts that are absorbed are excreted mostly unchanged in urine.

Half-Life: 2 hr.

Time/Action Profile

(effect on glucose absorption)

ROUTEONSETPEAKDURATION
POrapidwithin 1 hrunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: abdominal pain, diarrhea, flatulence

Hemat: low serum iron

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Glyset